Quintrio
Home

SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

OmniAb, Inc. Common Stock

OABI

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Last trade $5.01
Day change +$0.12 (+2.45%)
Day range $4.75 – $5.03
Volume 758,206
Market cap $713M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$713.26M
Price / earnings
—
Price / book
2.86×
Price / sales
17.74×
EV / sales
17.17×
EV / EBITDA
-27.77×

Profitability

Earnings per share
-$0.30
Return on assets
-14.94%
Return on equity
-17.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.21×
Quick ratio
4.21×
Cash ratio
1.36×

Cash flow

Price / cash flow
267.54×
Price / free cash flow
299.69×
Free cash flow
$2.38M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OABI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.99M$13.42M$14.43M$8.38M$2.24M$3.9M$4.15M$10.8M
Cost of revenue$309K$610K$15K$9K$29K$262K$3K$0
Gross profit$3.68M$12.81M$14.41M$8.37M$2.21M$3.64M$4.15M$10.8M
Selling, general and administrative$7.24M$6.65M$6.62M$6.84M$6.78M$7.68M$7.92M$7.36M
Research and development$9.55M$9.59M$9.64M$13.91M$10.38M$10.86M$12.6M$13.31M
Total operating expenses$20.05M$19.44M$22.24M$23.98M$20.35M$19.85M$23M$26.73M
Operating income-$16.37M-$6.64M-$7.83M-$15.61M-$18.14M-$16.22M-$18.84M-$15.92M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$15.86M-$6.21M-$7.27M-$14.55M-$17.69M-$15.76M-$18.31M-$15.22M
Income taxes-$127K-$353K$442K-$367K-$1.16M$119K-$106K-$2.16M
Net income-$15.73M-$5.86M-$7.71M-$14.18M-$16.53M-$15.88M-$18.2M-$13.07M
Net income attributable to common shareholders-$15.73M-$5.86M-$7.71M-$14.18M-$16.53M-$15.88M-$18.2M-$13.07M
EBITDA-$12.76M-$3.01M-$1.2M-$7.9M-$14.05M-$12.13M-$14.65M-$8.32M
Basic earnings per share-$0.12-$0.05-$0.06-$0.11-$0.14-$0.15-$0.17-$0.12
Diluted earnings per share-$0.12-$0.05-$0.06-$0.11-$0.14-$0.15-$0.17-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates

OmniAb, Inc. (OABI) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $3.99 million exceeding expectations by 10.12%. The company has outperformed the S&P 500 by 182.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Drugs industry ranks in the top 36% of Zacks industries.

Zacks Investment Research

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 shows no year-over-year change at -$0.35 per share, but analysts have raised estimates by 10.3% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.

The Motley Fool

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.

GlobeNewswire Inc.

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.